Skip to content

Search

Showing results for "clinical trials"

A randomized controlled evaluation of a secondary school mindfulness program for early adolescents: Do we have the recipe right yet?

Further research is required to identify the optimal age, content and length of mindfulness programs for adolescents in universal prevention settings.

Evaluation of the Western Australian Register of Developmental Anomalies: Thirty-five years of surveillance

The birth defects component of the Western Australian Register for Developmental Anomalies (WARDA-BD) was evaluated to assess its efficiency, effectiveness, and data quality

Impaired airway epithelial cell responses from children with asthma to rhinoviral infection

Human rhinovirus infection delays repair and inhibits apoptotic processes in epithelial cells from non-asthmatic and asthmatic children

Does somatosensation change with age in children and adolescents? A systematic review

How different somatosensory modalities develop across childhood into adolescence to use as a point of reference for children at risk of somatosensory

Dissecting the regulation of bile-induced biofilm formation in staphylococcus aureus

Wall teichoic acid may be important for protecting S. aureus against exposure to bile

Does somatosensation change with age in children and adolescents? A systematic review

Somatosensory modalities, such as touch, proprioception and haptic ability, greatly influence the achievement of developmental milestones for children.

A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders

The ThromboGenomics platform thus provides an affordable DNA-based test to diagnose patients suspected of having a known inherited BPD

Risk perception and risk-taking behaviour during adolescence: The influence of personality and gender

This study investigated the influence of personality characteristics and gender on adolescents' perception of risk and their risk-taking behaviour.

A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease

Specialized Proresolving Lipid Mediators are increased after 8 weeks n-3 fatty acid supplementation in patients with chronic kidney disease

Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis.

Two-thirds of individuals identified as at ultra-high risk for psychosis do not develop psychotic disorder over the medium term.